Nonetheless, in human melanoma and NSCLC TIL Tox expression is highest in cells that exhibit high PD-1, TIM-3 and CD39 co-expression, and Tox expression itself is a predictor of responsiveness to anti-PD-1 therapy [108]. This evidence concerns the gene HAVCR2 and melanoma.